Keith is a life science executive, originally trained in biochemistry & pharmacology (B.Sc. (Hons.), University of Edinburgh, UK, First/Summa cum laude and valedictorian). After a Ph.D. in physical biochemistry at University College London, the MRC’s National Institute for Medical Research (NIMR) and Wellcome Pharmaceuticals plc and a Keck fellowship in molecular biophysics at Washington University School of Medicine, St Louis USA, he held roles of increasing technical, leadership & executive responsibility in the UK at SmithKlineBeecham, GlaxoWellcome & GlaxoSmithKline Pharmaceuticals.
After management in GSK S.p.A (Italy), he was recruited to GSK Inc (USA) as Director of High Throughput Biology, ultimately being promoted to Vice President, Discovery Research Technologies with responsibility for 85 staff in 5 departments across the UK and USA. He is probably best known for co-leading the global strategic development of GSK’s research and laboratory capabilities in assay development and automated, ultra-high throughput, ultra-miniaturized molecular testing (100,000 tests/day in 1µL test volumes) via 10 international technology partnerships (~$150M ).
Following a role as Executive Director at Merck & Co/MSD, USA and 2010 Co-chair of the Industry society’s global annual scientific conference, he founded a successful molecular profiling contract research business in NC USA and which included the development of a molecular diagnostic for preterm birth. Returning to the UK, Keith founded a business development & interim management consultancy which supported the penetration of UK and US biomedical start-up companies into the Pharma/life science markets. After a family tragedy in August 2018, Keith decided to apply his experience and knowledge to help those less fortunate than himself. Spending a year to better understand the Philippines life science, healthcare and biomedical sector, he returned to the Philippines in November 2019 as Research Professor at Ateneo de Manila University. His research focuses on translational clinical research, particularly validation of proteins and nucleic acids as diagnostic biomarkers of (auto)immune and inflammatory diseases and their infection comorbidities.